IO Biotech: IO Biotech KOL Webinar Series – Part 1: A New Way to Kill Tumors? IO102-IO103 in Combination with Anti-PD-1 in Metastatic Melanoma


04/28/2022 - 04/28/2022
12:30 pm - 1:30 pm EDT
Part 1 of the IO Biotech KOL Webinar Series will feature presentations from:
  • Alexander Eggermont, MD, PhD (Princess Máxima Center for Pediatric Oncology)
  • Jason J. Luke, MD, FACP (University of Pittsburgh and UPMC Hillman Cancer Center)
Discussion will include:
  • The current treatment landscape and unmet medical need in treating patients with metastatic melanoma
  • IO Biotech’s investigational immunotherapeutic vaccines, IO102-IO103, targeting IDO and PD-L1 expressing cells, respectively
  • The data behind FDA’s decision to grant breakthrough therapy status based on the MM1636 Phase 1/2 clinical trial with 30 patients with metastatic melanoma receiving IO102-IO103 and anti-PD-1
A live question and answer session will follow.